|Day Low/High||1.68 / 1.76|
|52 Wk Low/High||0.91 / 9.78|
Use long-dated calls to take some of risk out of this inherently high-beta space.
CRBP has topline Phase 3 data for its primary compound Lenabasum for Systemic Sclerosis due out this summer.
Market players didn't see it coming and that is what helped it gain so much strength.
With cash levels high, those players who are not well-positioned for upside action are scrambling to put money to work and are helping to propel prices higher.
There have been some solid earnings reports, but they haven't provided a boost to the broader market.
If you are interested in Square longer term be patient and wait for the drama to end.
CRBP rocketed 53% Thursday on news of a deal with Jenrin Discovery to study 600 of their cannabinoid compounds.
These speculative frenzies all have a number of things in common.
Aggressive traders are beating the bushes looking for the next big mover.
Selloffs like the one in marijuana stocks present entry points, if this is your cup of tea.
On Monday, recreational use of marijuana will be legal in California, so let's visit 3 weed stocks.
Biotech companies show more energy than the rest of the market Monday.
The indices may test intraday lows, which we haven't seen at this point in the day in a very long time.
Corbus has surged 325% in 2016 due to Resunab which received an FDA "Fast Track" designation. Corbus CEO Dr. Yuval Cohen does not expect things to slow down anytime soon.
It’s been a hot M&A market for biotech companies developing treatments for rare diseases.